type here...

CATEGORIES

Pharmaceutics

LATEST

123...11Page 1 of 11

TRENDING

EDITORS CHOICE

ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

Medika Life -
ZEPOSIA, a treatment for multiple sclerosis is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation

How COVID and the Power of Now Killed Scientific Peer Review

Gil Bashe, Medika Life Editor -
How long do or should clinical trials take – well, it depends – but often years. Science takes time. It demands rigor and objectivity. It’s not a “now” pursuit.

Purdue Reformulated OxyContin to Reduce Abuse — Did They Succeed?

Jennifer Mittler-Lee B.S. Pharma -
OxyContin was neither superior to old-fashioned immediate-release oxycodone, a cheaper generic, nor did it offer any advantage over other opioids like morphine.

Ten mRNA Facts You Probably Didn’t Know About and Ten Nonsenses

Robert Turner, Founding Editor -
There's still a lot of nonsense that circulates about the Covid mRNA vaccines. Hidden amongst this noise are indisputable facts relating to these treatments,...

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories